PT  - JOURNAL ARTICLE
AU  - Nemudryi, Artem
AU  - Nemudraia, Anna
AU  - Wiegand, Tanner
AU  - Nichols, Joseph
AU  - Snyder, Deann T
AU  - Hedges, Jodi F
AU  - Cicha, Calvin
AU  - Lee, Helen
AU  - Vanderwood, Karl K
AU  - Bimczok, Diane
AU  - Jutila, Mark
AU  - Wiedenheft, Blake
TI  - SARS-CoV-2 genomic surveillance identifies naturally occurring truncations of ORF7a that limit immune suppression
AID  - 10.1101/2021.02.22.21252253
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.22.21252253
4099  - http://medrxiv.org/content/early/2021/03/10/2021.02.22.21252253.short
4100  - http://medrxiv.org/content/early/2021/03/10/2021.02.22.21252253.full
AB  - Over 200,000 whole genome sequences of SARS-CoV-2 have been determined for viruses isolated from around the world. These sequences have been critical for understanding the spread and evolution of SARS-CoV-2. Using global phylogenomics, we show that mutations frequently occur in the C-terminal end of ORF7a. We have isolated one of these mutant viruses from a patient sample and used viral chal-lenge experiments to demonstrate that Δ115 mutation results in a growth defect. ORF7a has been implicated in immune modulation, and we show that the C-terminal truncation results in distinct changes in interferon stimulated gene expression. Collectively, this work indicates that ORF7a mutations occur frequently and that these changes affect viral mechanisms responsible for suppressing the immune response.HighlightsORF7a mutations are found in SARS-CoV-2 genomes isolated from around the globe.ORF7a mutation results in a replication defect.An ORF7a mutation limits viral suppression of the interferon response.Competing Interest StatementB.W. is the founder of SurGene LLC, and VIRIS Detection Systems Inc. B.W., A. Nemudryi, and A. Nemudraia are inventors on patents related to CRISPR-Cas systems and applications thereof.Funding StatementResearch in the Wiedenheft lab is supported by the National Institutes of Health (1R35GM134867), the Montana State University Agricultural Experimental Station, the MJ Murdock Charitable Trust, the Gianforte Foundation and the MSU Office of the Vice President for Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Clinical samples were obtained with Montana State University Institutional Review Board approval (protocol #DB033020) and informed consent from patients undergoing testing for SARS-CoV-2 at Bozeman Health Deaconess HospitalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSARS-CoV-2 genome consensus sequences generated in the study were uploaded to GISAID (https://www.gisaid.org/), accession IDs are provided in Supplemental Table S1